Asia-Pacific Diabetes Care Drugs Market - Growth, Trends, and Forecast (2019 - 2024)

Market Overview

The Asia-Pacific market for diabetes drugs is estimated to value USD 23.8 billion in 2019, and the market is expected to grow at the CAGR of 4.82%, during the forecast period.

Over the past few decades, Asian countries have witnessed a rapid increase in diabetes patients, especially those with type 2 diabetes. Developing countries have more than 70% of the global diabetes population.

The Asian population gets diabetes at a younger age in comparison to the Western population. The reason for this early diabetes development is the sudden change in lifestyle, due to rapid economic growth.

Asia contributes approximately 60% of the total diabetes patients in the world. The most obvious reason for this is that two of the most populated countries in the world are in Asia. 

Scope of the Report

The Asia-Pacific diabetes drugs report covered by category (insulin, oral anti-diabetic drugs, non-insulin injectable drugs, and combination drugs), by segment (basal or long-acting, bolus or fast-acting, traditional human insulin drugs, insulin biosimilars, GLP-1 receptor agonists, alpha-glucosidase inhibitors, DPP-4 inhibitors, and SGLT-2 inhibitors), and by countries.

Key Market Trends 

Oral Anti-Diabetes Drugs Take 67% of the Asia-Pacific Diabetes Drugs Market.

The use of oral anti-diabetes drugs is rising, due to the fact that new generation oral drugs, such as DPP-4 and SGLT-2, reduce the rate of CV risk in diabetes patients. 

SGLT-2 and GLP-1 are linked to lowering the mortality rate more effectively than DPP-4 inhibitors. 

Meglitinide and sulfonylureas are oral hypoglycemic drugs that directly arouse the discharge of insulin from pancreatic beta cells. They hold a significant market share, of 14.27% and 9.62%, respectively, in the Asia-Pacific anti-diabetics drugs market.

China and Japan Occupy more than a 50% Share in the Asia-Pacific Diabetes Drugs Market.

In the Asia-Pacific region, China and Japan have recognized as potential developing markets, due to the growing diabetic population in this region.

Japan is a mature market, with some associated challenges, like slow economic growth, the aging population, and increased competition. One particular challenge in this region is the growing preference for oral anti-diabetics among type-2 diabetic patients, thereby, leading to a negative insulin volume development.

China has the highest market share and is expected to grow with a steady CAGR of 4%. It also contributes 15% to the global diabetes drugs market. 

The country is witnessing a significant increase in the number of generic drug manufacturers. Furthermore, the leading global players in the market studied are facing intense competition from the regional players.

Competitive Landscape

The Asia-Pacific diabetes care drugs market is highly fragmented, with a few major manufacturers gaining presence in major countries of the Asia-Pacific market, while the remaining market comprises other local or region-specific manufacturers. 

Mergers and acquisitions that happened between players in the recent past helped companies strengthen their market presence, as well as driving innovations, helping the diabetes drugs market to increase in the Asia-Pacific region. For instance, Biocon has launched its insulin glargine biosimilar, in Japan and Malaysia, partnering with local manufacturers for further commercialization. 

Reasons to Purchase this report:

– The market estimate (ME) sheet in Excel format

– Report customization as per the client’s requirements

– 3 months of analyst support

1 INTRODUCTION

1.1 Study Deliverables

1.2 Study Assumptions

1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

4.1 Market Overview

4.2 Drivers

4.3 Restraints

4.4 Porter’s Five Forces Analysis

4.4.1 Bargaining Power of Suppliers

4.4.2 Bargaining Power of Consumers

4.4.3 Threat of New Entrants

4.4.4 Threat of Substitute Products and Services

4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

5.1 By Drug

5.1.1 Oral Anti-diabetic Drugs

5.1.1.1 Biguanides (Value and Volume 2012-2024)

5.1.1.1.1 Metformin

5.1.1.2 Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)

5.1.1.2.1 Alpha – Glucosidase Inhibitors

5.1.1.3 Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)

5.1.1.3.1 Bromocriptin (Cycloset)

5.1.1.4 Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)

5.1.1.4.1 Invokana (Canagliflozin)

5.1.1.4.2 Jardiance (Empagliflozin)

5.1.1.4.3 Farxiga/Forxiga (Dapagliflozin)

5.1.1.4.4 Suglat (Ipragliflozin)

5.1.1.5 Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

5.1.1.5.1 Januvia (Sitagliptin)

5.1.1.5.2 Onglyza (Saxagliptin)

5.1.1.5.3 Tradjenta (Linagliptin)

5.1.1.5.4 Vipidia/Nesina (Alogliptin)

5.1.1.5.5 Galvus (Vildagliptin)

5.1.1.6 Sulfonylureas (Value and Volume 2012-2024)

5.1.1.6.1 Sulfonylureas

5.1.1.7 Meglitinides (Value and Volume 2012-2024)

5.1.1.7.1 Meglitinides

5.1.2 Insulin

5.1.2.1 Basal or Long-acting Insulins

5.1.2.1.1 Lantus (Insulin Glargine)

5.1.2.1.2 Levemir (Insulin Detemir)

5.1.2.1.3 Toujeo (Insulin Glargine)

5.1.2.1.4 Tresiba (Insulin Degludec)

5.1.2.1.5 Basaglar (Insulin Glargine)

5.1.2.2 Bolus or Fast-acting Insulins

5.1.2.2.1 NovoRapid/Novolog (Insulin Aspart)

5.1.2.2.2 Humalog (Insulin Lispro)

5.1.2.2.3 Apidra (Insulin Glulisine)

5.1.2.3 Traditional Human Insulins

5.1.2.3.1 Novolin/Actrapid/Insulatard

5.1.2.3.2 Humilin

5.1.2.3.3 Insuman

5.1.2.4 Biosimilar Insulins

5.1.2.4.1 Insulin Glargine Biosimilars

5.1.2.4.2 Human Insulin Biosimilars

5.1.3 Non-insulin Injectable Drugs

5.1.3.1 GLP-1 Receptor Agonists

5.1.3.1.1 Victoza (Liraglutide)

5.1.3.1.2 Byetta (Exenatide)

5.1.3.1.3 Bydureon (Exenatide)

5.1.3.1.4 Trulicity (Dulaglutide)

5.1.3.1.5 Lyxumia (Lixisenatide)

5.1.3.2 Amylin Analogue

5.1.3.2.1 Symlin (Pramlintide)

5.1.4 Combination Drugs

5.1.4.1 Insulin Combinations

5.1.4.1.1 NovoMix (Biphasic Insulin Aspart)

5.1.4.1.2 Ryzodeg (Insulin Degludec and Insulin Aspart)

5.1.4.1.3 Xultophy (Insulin Degludec and Liraglutide)

5.1.4.2 Oral Combination

5.1.4.2.1 Janumet (Sitagliptin and Metformin HCl)

5.2 Geography

5.2.1 Asia-Pacific

5.2.1.1 Australia (Value and Volume 2012-2024)

5.2.1.1.1 Oral Anti-diabetic Drugs

5.2.1.1.2 Insulin

5.2.1.1.3 Non-Insulin Injectable Drugs

5.2.1.1.4 Combination Drugs

5.2.1.1.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.2 China (Value and Volume 2012-2024)

5.2.1.2.1 Oral Anti-diabetic Drugs

5.2.1.2.2 Insulin

5.2.1.2.3 Non-Insulin Injectable Drugs

5.2.1.2.4 Combination Drugs

5.2.1.2.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.3 India (Value and Volume 2012-2024)

5.2.1.3.1 Oral Anti-diabetic Drugs

5.2.1.3.2 Insulin

5.2.1.3.3 Non-Insulin Injectable Drugs

5.2.1.3.4 Combination Drugs

5.2.1.3.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.4 Indonesia (Value and Volume 2012-2024)

5.2.1.4.1 Oral Anti-diabetic Drugs

5.2.1.4.2 Insulin

5.2.1.4.3 Non-Insulin Injectable Drugs

5.2.1.4.4 Combination Drugs

5.2.1.4.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.5 Japan (Value and Volume 2012-2024)

5.2.1.5.1 Oral Anti-diabetic Drugs

5.2.1.5.2 Insulin

5.2.1.5.3 Non-Insulin Injectable Drugs

5.2.1.5.4 Combination Drugs

5.2.1.5.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.6 Malaysia (Value and Volume 2012-2024)

5.2.1.6.1 Oral Anti-diabetic Drugs

5.2.1.6.2 Insulin

5.2.1.6.3 Non-Insulin Injectable Drugs

5.2.1.6.4 Combination Drugs

5.2.1.6.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.7 Philippines (Value and Volume 2012-2024)

5.2.1.7.1 Oral Anti-diabetic Drugs

5.2.1.7.2 Insulin

5.2.1.7.3 Non-Insulin Injectable Drugs

5.2.1.7.4 Combination Drugs

5.2.1.7.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.8 South Korea (Value and Volume 2012-2024)

5.2.1.8.1 Oral Anti-diabetic Drugs

5.2.1.8.2 Insulin

5.2.1.8.3 Non-Insulin Injectable Drugs

5.2.1.8.4 Combination Drugs

5.2.1.8.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.9 Thailand (Value and Volume 2012-2024)

5.2.1.9.1 Oral Anti-diabetic Drugs

5.2.1.9.2 Insulin

5.2.1.9.3 Non-Insulin Injectable Drugs

5.2.1.9.4 Combination Drugs

5.2.1.9.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.10 Vietnam (Value and Volume 2012-2024)

5.2.1.10.1 Oral Anti-diabetic Drugs

5.2.1.10.2 Insulin

5.2.1.10.3 Non-Insulin Injectable Drugs

5.2.1.10.4 Combination Drugs

5.2.1.10.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

5.2.1.11 Rest of Asia Pacific (Value and Volume 2012-2024)

5.2.1.11.1 Oral Anti-diabetic Drugs

5.2.1.11.2 Insulin

5.2.1.11.3 Non-Insulin Injectable Drugs

5.2.1.11.4 Combination Drugs

5.2.1.11.5 By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

6 MARKET INDICATORS

6.1 Type-1 Diabetes Population (2012-2024)

6.2 Type-2 Diabetes Population (2012-2024)

7 COMPETITIVE LANDSCAPE

7.1 Company Profiles

7.1.1 Takeda

7.1.2 Pfizer

7.1.3 Eli Lilly

7.1.4 Janssen Pharmaceuticals

7.1.5 Astellas

7.1.6 Boehringer Ingelheim

7.1.7 Merck And Co.

7.1.8 AstraZeneca

7.1.9 Bristol Myers Squibb

7.1.10 Novartis

7.1.11 Sanofi

8 MARKET OPPORTUNITIES AND FUTURE TRENDS

MARKET SEGMENTATION

By Drug

Oral Anti-diabetic Drugs

Biguanides (Value and Volume 2012-2024)

Metformin

Alpha – Glucosidase Inhibitors (Value and Volume 2012-2024)

Alpha – Glucosidase Inhibitors

Dopamine -D2 Receptor Agonist (Value and Volume 2012-2024)

Bromocriptin (Cycloset)

Sodium-glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)

Invokana (Canagliflozin)

Jardiance (Empagliflozin)

Farxiga/Forxiga (Dapagliflozin)

Suglat (Ipragliflozin)

Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors (Value and Volume 2012-2024)

Januvia (Sitagliptin)

Onglyza (Saxagliptin)

Tradjenta (Linagliptin)

Vipidia/Nesina (Alogliptin)

Galvus (Vildagliptin)

Sulfonylureas (Value and Volume 2012-2024)

Sulfonylureas

Meglitinides (Value and Volume 2012-2024)

Meglitinides

Insulin

Basal or Long-acting Insulins

Lantus (Insulin Glargine)

Levemir (Insulin Detemir)

Toujeo (Insulin Glargine)

Tresiba (Insulin Degludec)

Basaglar (Insulin Glargine)

Bolus or Fast-acting Insulins

NovoRapid/Novolog (Insulin Aspart)

Humalog (Insulin Lispro)

Apidra (Insulin Glulisine)

Traditional Human Insulins

Novolin/Actrapid/Insulatard

Humilin

Insuman

Biosimilar Insulins

Insulin Glargine Biosimilars

Human Insulin Biosimilars

Non-insulin Injectable Drugs

GLP-1 Receptor Agonists

Victoza (Liraglutide)

Byetta (Exenatide)

Bydureon (Exenatide)

Trulicity (Dulaglutide)

Lyxumia (Lixisenatide)

Amylin Analogue

Symlin (Pramlintide)

Combination Drugs

Insulin Combinations

NovoMix (Biphasic Insulin Aspart)

Ryzodeg (Insulin Degludec and Insulin Aspart)

Xultophy (Insulin Degludec and Liraglutide)

Oral Combination

Janumet (Sitagliptin and Metformin HCl)

Geography

Asia-Pacific

Australia (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

China (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

India (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Indonesia (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Japan (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Malaysia (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Philippines (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

South Korea (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Thailand (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Vietnam (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)

Rest of Asia Pacific (Value and Volume 2012-2024)

Oral Anti-diabetic Drugs

Insulin

Non-Insulin Injectable Drugs

Combination Drugs

By Company (Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca, Astellas, Janssen, Merck, and Others)